TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15562885
Drug: Cetirizine hydrochloride
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine hydrochloride (10 mg daily for 4 days)
Study: 3044872
Drug: Codergocrine mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codergocrine mesylate, increasing dosage over 12 weeks
Study: 16153780
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1000mg)
Study: 12816696
Drug: OAC triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC triple therapy
Study: 1817628
Drug: Morphine 3
Normalized name: apomorphine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 3 mg plus Clonidine 75 micrograms
Study: 31842036
Drug: Topical 1.5%
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5% Azithromycin (AZ) administered as a unit dose
Study: 31842036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical AZ)
Study: 31823650
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 15 g extract granule daily for 4 weeks
Study: 23359067
Drug: HM10460A 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM10460A 45 μg/kg
Study: 23359067
Drug: HM10460A 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM10460A 135 μg/kg
Study: 23359067
Drug: HM10460A 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM10460A 350 μg/kg
Study: 21323679
Drug: Alcohol intoxication
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intoxication (peak breath alcohol concentration of 0.11 ± 0.01 g%)
Study: 17728695
Drug: Enteral glutamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral glutamine, 0.65 g kg(‐1) daily for 7 days
Study: 16720935
Drug: Whole-body-vibration (WBV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body-vibration (WBV) treatment, 5 series of 60 seconds each
Study: 16720935
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no WBV treatment)
Study: 16720935
Drug: Whole-body-vibration (WBV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body-vibration (WBV) treatment (cross-over design)
Study: 16720935
Drug: Whole-body-vibration (WBV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body-vibration (WBV) treatment
Study: 15533869
Drug: Baseline NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline NT-proBNP levels >250 ng/L
Study: 15533869
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of rapid decline in NT-proBNP levels (< or =250 ng/L)
Study: 15533869
Drug: Rise in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rise in NT-proBNP levels over 72 hours to >250 ng/L
Study: 9231658
Drug: Antecedent hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycemia of 3.9 mmol/l
Study: 9231658
Drug: Antecedent hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycemia of 3.3 mmol/l
Study: 9231658
Drug: Antecedent hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycemia of 2.9 mmol/l
Study: 8029784
Drug: Melipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses for 2 and 4 weeks
Study: 8029784
Drug: Melipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses
Study: 3323258
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg at bedtime for four days prior to chloroquine administration)
Study: 29402789
Drug: Hyoscine N-Butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-Butylbromide (20 mg)
Study: 26797664
Drug: Self-administered computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered computer therapy for apraxia of speech
Study: 22529257
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) with fluorouracil 800 mg/m(2)/d IV infusion on days 1-4 and 29-32, and cisplatin 80 mg/m(2) IV on days 1 and 29, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy.
Study: 22529257
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) with fluorouracil and cisplatin, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Study: 22529257
Drug: Concomitant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy (reference arm).
Study: 22529257
Drug: Concomitant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Study: 22529257
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) effect comparison between groups A and B versus C and D.
Study: 22529257
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose effect comparison between groups A and C versus B and D.
Study: 20534421
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEpo) - 3 consecutive intravenous doses (24,000 IU)
Study: 17313499
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin)
Study: 17313499
Drug: Modified eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified eradication therapy (standard triple therapy plus bovine lactoferrin and probiotics)
Study: 29673831
Drug: Hypovitaminosis D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypovitaminosis D defined as serum 25-hydroxyvitamin D concentration (25OHD) ≤30 ng/mL
Study: 29673831
Drug: Hypovitaminosis D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypovitaminosis D ≤ 30 ng/mL
Study: 27083763
Drug: Zinc plus
Normalized name: Zinc plus Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc plus multivitamins (20 mg elemental zinc, vitamin A 1000 IU, vitamin D 200 IU, B1 10 mg, B2 3 mg, B6 1 mg, B12 10 μg, nicotinamide 40 mg)
Study: 24945737
Drug: silymarin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin (420 mg/day)
Study: 20739647
Drug: Sertraline (flexible-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (flexible-dose up to 200 mg)
Study: 15232334
Drug: Nalmefene 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 5 mg
Study: 15232334
Drug: Nalmefene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 40 mg
Study: 11758326
Drug: Propofol (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1% propofol 20 ml with 2 ml of normal saline)
Study: 7706597
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day sugar added to meals
Study: 3580232
Drug: Sodium thiosulphate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulphate 10.6‐38.5 mg kg‐1
Study: 23943468
Drug: Intermittent, CD4-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent, CD4-guided antiretroviral therapy (ART)
Study: 9105355
Drug: Autogenous posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous posterior pharyngeal wall augmentation using a rolled superiorly based pharyngeal myomucosal flap
Study: 9105355
Drug: Autogenous posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenous posterior pharyngeal wall augmentation
Study: 3991280
Drug: Furosemide, 2
Normalized name: Furosemide, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 2 mg/kg orally at diagnosis followed by 1 mg/kg 12 hours later if symptoms persisted
Study: 28558139
Drug: Surfactant solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant solution
Study: 24267864
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with levothyroxine (n=45; 61.6%)
Study: 24267864
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with levothyroxine
Study: 19726314
Drug: Tiopronin enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin enteric capsules (200 mg)
Study: 19726314
Drug: Tiopronin tablets
Normalized name: tiopronin Oral Tablet
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiopronin tablets (200 mg)
Study: 17416857
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (wD)
Study: 9626635
Drug: Oral risedronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate, 30 mg/day for 84 days
Study: 9626635
Drug: Oral risedronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate, 30 mg/day for 84 days (repeated administration)
Study: 7882703
Drug: Sustained-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release ibuprofen (1600 mg taken in the evening)
Study: 7882703
Drug: Placebo (substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (substituted for a single dose of active treatment)
Study: 2979246
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg o.m.
Study: 23577799
Drug: Flaxseed lignan
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan (543 mg/day in BeneFlax)
Study: 21323532
Drug: Cellular phone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular phone reminder system (ARemind) - personalized text messages daily
Study: 21323532
Drug: Beeper (BP)
Normalized name: Titanium Dioxide 0.38 g in 4.25 g TOPICAL POWDER [Purminerals 4 in 1 Makeup SPF 15 Deeper]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beeper (BP) - reminder beep at the time of dosing
Study: 19175889
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 microg once daily (QD)
Study: 14997197
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g PSK plus 300 mg UFT orally each day for 2 years
Study: 14997197
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg UFT alone orally each day for 2 years
Study: 14997197
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g PSK plus 300 mg UFT in stage III patients
Study: 14997197
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg UFT alone in stage III patients
Study: 20229169
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g PSK plus 300 mg UFT
Study: 7780046
Drug: Stavudine 5
Normalized name: stavudine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 5 mg
Study: 7780046
Drug: Stavudine 10
Normalized name: stavudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 10 mg
Study: 7780046
Drug: Stavudine 20
Normalized name: stavudine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 20 mg
Study: 2083186
Drug: iproplatin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: iproplatin (240 mg/m2)
Study: 2083186
Drug: cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (100 mg/m2)
Study: 2083186
Drug: carboplatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: carboplatin (300 mg/m2)
Study: 40440
Drug: 50 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/day of lecithin
Study: 28260458
Drug: 450 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/d valganciclovir
Study: 28260458
Drug: 900 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/d valganciclovir
Study: 24727123
Drug: Simeprevir 100mg
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin for 12 weeks then response-guided therapy with peginterferon α‐2a/ribavirin for 12 or 36 weeks
Study: 24727123
Drug: Simeprevir 100mg
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin
Study: 18251154
Drug: Triple‐plus‐probiotics group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple‐plus‐probiotics group (1 week of PPI-based triple therapy + 8 weeks of probiotics)
Study: 18251154
Drug: Triple‐only group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple‐only group (1 week of PPI-based triple therapy without probiotics)
Study: 16340102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deep brain stimulation, pharmacotherapy, and rehabilitation training
Study: 9787684
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol in frequent low doses (0.075 mg/kg every 30 minutes)
Study: 9787684
Drug: Salbutamol in
Normalized name: Product containing salbutamol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol in frequent low doses
Study: 9787684
Drug: Salbutamol in
Normalized name: Product containing salbutamol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol in hourly high doses (0.15 mg/kg every 60 minutes)
Study: 7625415
Drug: Sublingual estradiol‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual estradiol‐17 beta (1 mg)
Study: 31930464
Drug: Relationship characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship characteristics (different ethnicity, poor socioeconomic status, difference in incomes, living in a rental property, alcohol and drug use, unprocessed previous history of physical violence)
Study: 25404126
Drug: Intermittent Screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Screening and Treatment (IST) with artemether-lumefantrine (AL)
Study: 25404126
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Study: 21070457
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 24‐mg/mL cohesive gel and onabotulinumtoxinA
Study: 12548091
Drug: Intravenous epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoprostenol
Study: 9360182
Drug: Laminaria tents
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria tents + 4 mg PGE2 gel
Study: 9360182
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel alone
Study: 1548570
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg p.o. daily)
Study: 1548570
Drug: Trimethoprim/sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg p.o. daily)
Study: 4033132
Drug: 0.23 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.23 g/kg alcohol
Study: 4033132
Drug: 0.46 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.46 g/kg alcohol
Study: 4033132
Drug: 0.12 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 g/kg alcohol
Study: 18164094
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (0.15 U/kg)
Study: 18164094
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.15 U/kg)
Study: 12892384
Drug: Magnesium-orotate (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-orotate (3000 mg/day for 90 days)
Study: 10756246
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of contrast agent at different rates (3 rates, 10 or 20 minutes duration).
Study: 10756246
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of contrast agent.
Study: 8650428
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil ethyl ester (Esapent, 5.1 g/day)
Study: 1501052
Drug: Intravenous IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IgM enriched immunoglobulin
Study: 6593146
Drug: 0.2% neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% neutral solution of sodium fluoride, 10 ml, rinsed every second week during the school year
Study: 29575737
Drug: Ultrasound-guided intraarticular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intraarticular glucocorticoid injections
Study: 29575737
Drug: Palpation-guided intraarticular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided intraarticular glucocorticoid injections
Study: 27561366
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without DTCP (Group A)
Study: 25327602
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of plant sterol esters a day (treatment group, n = 30)
Study: 19758267
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g MMF plus low-dose tacrolimus
Study: 19083666
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (twice weekly from partners from 20 weeks gestation until the end of pregnancy)
Study: 17217216
Drug: Pentoxifylline (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400mg 3 times daily, as coated, sustained release tablets)
Study: 17217216
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug group (multivitamin and local heat therapy)
Study: 14710168
Drug: Additional protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional protein group (n=73) received 48.2 g/day additional protein.
Study: 9258974
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of baclofen
Study: 9258974
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of baclofen
Study: 8435362
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days + Verapamil (VPL) 480 mg orally one day before and during EPI
Study: 8435362
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days without VPL
Study: 3579676
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta administered intrathecally (IT)
Study: 30328305
Drug: Fiber post
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber post placed in both buccal and palatal canals (Group 5)
Study: 23364390
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50 μg bid (FP100)
Study: 23364390
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 μg bid (FP500)
Study: 20385870
Drug: ST-246 250
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 250 mg/day
Study: 20385870
Drug: ST-246 400
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 400 mg/day
Study: 20385870
Drug: ST-246 800
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 800 mg/day
Study: 6391928
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg in the morning, placebo in the evening
Study: 6391928
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg in the evening, placebo in the morning
Study: 6391928
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg in the morning and 500 mg in the evening
Study: 31383465
Drug: Intraperitoneal antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal antibiotic irrigation (polymyxin B, 500,000 units/L)
Study: 26149170
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of bevacizumab
Study: 26149170
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of ranibizumab
Study: 20156032
Drug: P-OM3 4
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-OM3 4 g/day + simvastatin 40 mg/day
Study: 20156032
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + simvastatin 40 mg/day